Search research articles
Contact Us
Filters
Showing results (61-70 of 70) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 70 results.
European Heart Journal
|
August 29, 2022
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Florian Kronenberg, Samia Mora, Erik S G Stroes, et al.
European Heart Journal
|
September 2, 2021
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society
Henry N Ginsberg, Chris J Packard, M John Chapman, et al.
European Heart Journal
|
March 27, 2018
New prospects for PCSK9 inhibition?
Ulf Landmesser, M John Chapman, Jane K Stock, et al.
Nature Medicine
|
April 17, 2026
Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Nature Medicine
|
February 27, 2026
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
European Cardiology
|
January 13, 2022
Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia
Natalie Koh, Brian A Ference, Stephen J Nicholls, et al.
European Heart Journal
|
April 27, 2017
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A Ference, Henry N Ginsberg, Ian Graham, et al.
JAMA Cardiology
|
June 22, 2018
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis
Stephen Burgess, Brian A Ference, James R Staley, et al.
GMS Health Innovation and Technologies
|
October 31, 2022
The time is now: Achieving FH paediatric screening across Europe - The Prague Declaration
Nicole Bedlington, Marianne Abifadel, Birgit Beger, et al.
European Heart Journal
|
February 14, 2020
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Jan Borén, M John Chapman, Ronald M Krauss, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 70) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 70 results.
European Heart Journal
|
August 29, 2022
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Florian Kronenberg, Samia Mora, Erik S G Stroes, et al.
European Heart Journal
|
September 2, 2021
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society
Henry N Ginsberg, Chris J Packard, M John Chapman, et al.
European Heart Journal
|
March 27, 2018
New prospects for PCSK9 inhibition?
Ulf Landmesser, M John Chapman, Jane K Stock, et al.
Nature Medicine
|
April 17, 2026
Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
Nature Medicine
|
February 27, 2026
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Stephen J Nicholls, Adam J Nelson, Marc Ditmarsch, et al.
European Cardiology
|
January 13, 2022
Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia
Natalie Koh, Brian A Ference, Stephen J Nicholls, et al.
European Heart Journal
|
April 27, 2017
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A Ference, Henry N Ginsberg, Ian Graham, et al.
JAMA Cardiology
|
June 22, 2018
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis
Stephen Burgess, Brian A Ference, James R Staley, et al.
GMS Health Innovation and Technologies
|
October 31, 2022
The time is now: Achieving FH paediatric screening across Europe - The Prague Declaration
Nicole Bedlington, Marianne Abifadel, Birgit Beger, et al.
European Heart Journal
|
February 14, 2020
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Jan Borén, M John Chapman, Ronald M Krauss, et al.
Page
of 7